Side effect profiles of new antipsychotic agents

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages

  Casey, Daniel E ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SOMNOLENCE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CLOZAPINE; DYSKINESIA, DRUG-INDUCED; HUMANS; IMIDAZOLES; INDOLES; NEUROLEPTIC MALIGNANT SYNDROME; PIRENZEPINE; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEIZURES; SLEEP; WEIGHT GAIN;

EID: 10544243792     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Deniker P. Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B, eds. Discoveries in Biological Psychiatry. Baltimore, Md: Ayd Medical Communications; 1984:155-164
2. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
3. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99:S47-S53
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
5. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974;31:58-61
6. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 1989;251:238-246
7. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
8. 2 receptors. Psychopharmacology (Berl) 1993;112:S40-S54
9. Moore NA, Calligaro DO, Wong TD, et al. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 1993;2:281-293
10. Sanchez C, Arnt J, Dragsled N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development and Research 1991;22:239-250
11. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995:546-565
12. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10:105-114
13. Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991;29:1215-1219
14. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
15. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
16. Beasley CM, Sanger W, Satterlee G, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
17. van Kammen DP, McEvoy JP, Targum S, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-175
18. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. In: Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 1995; San Juan, Puerto Rico. Abstract 278
19. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-33
20. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A19 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104
21. Casey DE. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 1989;25:457-459
22. 2 and serotonin mechanisms. In: Fog R, Gerlach J, Hemmingsen R, eds. Schizophrenia: An Integrated View. Copenhagen, Denmark: Munksgaard Press; 1995: 287-297
23. Casey DE. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology (Berl) 1996;124:134-140
24. Saltz BL, Woemer M, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406
25. Street JS, Tamura RN, Sanger TM, et al. A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. In: Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 1995; San Juan, Puerto Rico. Abstract 274
26. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371
27. Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987; 144:1344-1346
28. Reddig S, Minnema AM, Tandon R. Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 1993;5:25-27
29. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228-1229
30. Lee H, Ryan J, Mullett G, et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Human Psychopharmacology 1994;9:303-305